VYNE Therapeutics Inc. financial data

Symbol
VYNE on Nasdaq
Location
Bridgewater, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 14 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 520% % -41%
Debt-to-equity 23% % 61%
Return On Equity -78% % -76%
Return On Assets -63% % -64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25,472,165 shares 73%
Common Stock, Shares, Outstanding 19,773,784 shares 36%
Entity Public Float $28,200,000 USD 115%
Common Stock, Value, Issued $2,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 42,759,000 shares 0.41%
Weighted Average Number of Shares Outstanding, Diluted 42,759,000 shares 0.41%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $476,000 USD -2.1%
Research and Development Expense $30,937,000 USD 78%
General and Administrative Expense $12,139,000 USD -13%
Costs and Expenses $43,076,000 USD 38%
Operating Income (Loss) $42,600,000 USD -38%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $38,517,000 USD -38%
Income Tax Expense (Benefit) $4,000 USD
Net Income (Loss) Attributable to Parent $38,545,000 USD -36%
Earnings Per Share, Basic 0 USD/shares -153%
Earnings Per Share, Diluted 0 USD/shares -153%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $22,047,000 USD -26%
Marketable Securities, Current $17,600,000 USD -64%
Assets, Current $44,343,000 USD -47%
Property, Plant and Equipment, Net $102,000 USD
Operating Lease, Right-of-Use Asset $32,000 USD -79%
Assets $44,718,000 USD -48%
Employee-related Liabilities, Current $819,000 USD 11%
Accrued Liabilities, Current $3,578,000 USD -29%
Liabilities, Current $5,836,000 USD -50%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $5,836,000 USD -50%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,000 USD 97%
Retained Earnings (Accumulated Deficit) $745,536,000 USD -5.5%
Stockholders' Equity Attributable to Parent $38,882,000 USD -48%
Liabilities and Equity $44,718,000 USD -48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,461,000 USD -44%
Net Cash Provided by (Used in) Financing Activities $87,000 USD -1640%
Net Cash Provided by (Used in) Investing Activities $19,831,000 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 19,773,784 shares 36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,283,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $22,047,000 USD -26%
Deferred Tax Assets, Valuation Allowance $100,679,000 USD 12%
Deferred Tax Assets, Gross $100,679,000 USD 12%
Operating Lease, Liability $99,000 USD -54%
Depreciation $6,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $38,489,000 USD -35%
Lessee, Operating Lease, Liability, to be Paid $101,000 USD -56%
Property, Plant and Equipment, Gross $117,000 USD
Operating Lease, Liability, Current $25,000 USD -79%
Lessee, Operating Lease, Liability, to be Paid, Year One $101,000 USD -20%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,000 USD -86%
Deferred Tax Assets, Operating Loss Carryforwards $75,922,000 USD 4.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Unrecognized Tax Benefits $2,566,000 USD 4.4%
Additional Paid in Capital $784,418,000 USD 0.32%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $6,000 USD
Share-based Payment Arrangement, Expense $2,725,000 USD -21%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%